Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Approved with a note from FDA!
The note puts a quash on any
Massive profit they were expecting!
Should open with euphoria pump
And fade!
That's my take.
Give it a week.
BIIB gets FDA approval...stock halted.
You are surely correct and yet things are so corrupt I think it could surely go that way. I was getting emails from the head of ALZ ORG telling everyone to work for it's approval. Sent him one asking how much they were paying him and how he slept at night
It can’t be worse than Jan 6th!!!
? update me. I haven't been following BIIB for a cool minute
June 7th will be a real national embarrassment if it goes the distance with aducamab
I just read the transcript of the earnings conference, and it seems earning projections factor in approval of a new alzheimers drug still being evaluated by the FDA, which has had a negative vote in the past. Can anyone tell me why they are so confident? None of the questions asked seem to address that directly, although a couple mentioned the new drug adu.
add another rope a dope to biogens belt notches..
greatest scam ever..just terrible..
hey Tatonka..yeah it's the same damn cliff..
there is ZERO doubt that a great therapeutic is near by..
Anavex, Annovis, et al..
but this tub of deceit wont get out of the way for REAL HOPE..
DISGUSTING..I calm myself withknowing that someday this drug MAY be an AJUNCTIVE to a real therapy..but my guess is ..
Anavex and ANNOVIS will NEVER need aduscamandrob....
I would take a chance on an Alzheimer stock with a extreme potential rather than a gamble on Biogen with no FDA approval jet.
Just my view of course.
Take a look at CBBT your competitor priced at .12 usd
Totally agree, saw $CBBT making huge gains over the last three months
Cerebain Biotech is priced at 0.12.
If they succeed the Alzheimer approval.
Better priced than Biogen....
Who will winn the Alzheimer medicin....
Imo cbbt a once in a lifetime chance...
Anavex now in trials for PDD, Rett, Alz with patent Approval now for Cerebal palsy, MS, Autism, Angelman's is going to rock the CNS world and leave Biogen with their pig with lipstick Aducamab. Better act soon cause licenses will go quickly once Rett results data comes out by Dec 15th and additional data on PDD.
and you dont think that is priced in? $300+ to $240 kerplunk?
I dont know if you are aware the great Alzheimer lie has several class actions on the table. Not good when BPs lie.
Chart says differently and will re-enter if there is any sell off to $220s or lower
http://schrts.co/rcwpuGeC
Weirdly this stock goes up and down almost the exact same amount each time they release through a PR that I heir Alzheimer’s drug has a chance to be efficacious. Cant take these guys serious and cant laugh about it either now that its the fourth time!
AVXL is ripe for the picking, be it institutional, small investor, partnership or buyout.
Time for a new ethical CEO. Perhaps the shareholder could buy AVXL before Eisai buys them out.
Unfortunately, this thumb’s down vote is not binding. The FDA could still approve aducanumab:
“The nonbinding vote by an advisory panel for the Food and Drug Administration does not mean the agency won’t approve the drug, aducanumab, made by Biogen. But it signals that many experts in the field are not convinced of its effectiveness, another major setback in the long journey to find a treatment for Alzheimer’s that works.”
https://www.nytimes.com/2020/11/06/health/aducanumab-alzheimers-drug-fda-panel.html
FDA gives Biogen's Aducanumab thumbs down 8-1 vote.
"The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 8-1 (2 uncertain) that the Phase 3 EMERGE study (the one that was successful at the higher dose) evaluating Biogen's (NASDAQ:BIIB) aducanumab in patients with mild Alzheimer's disease was not enough to demonstrate efficacy.
Shares will be poised for a significant drop when trading resumes."
Good news for Anavex AVXL which Alzheimer drug shows safety and efficacy.
Link;
https://seekingalpha.com/news/3633299-fda-thumbs-down-on-biogen-alzheimers-candidate-aducanumab
Breaking News: $BIIB Everything Investors Need to Know About Biogen's FDA Meeting Tomorrow
It's finally time for the Food and Drug Administration's committee of outside experts to decide on aducanumab, Biogen 's (NASDAQ: BIIB) controversial drug for Alzheimer's disease . Recent events have put shares on a roller coaster. The ride culminated with a 44% spike yester...
Find out more BIIB - Everything Investors Need to Know About Biogen's FDA Meeting Tomorrow
BREAKING NEWS: $BIIB S&P 500 Bucks Election Uncertainty, Rockets Higher on Tech Stock Surge; Huge Gains for Healthcare Stocks
So much for uncertainty being bad for stocks. The S&P 500 Index (SNPINDEX: ^GSPC) surged up 74 points, or more than 2.2%, on Nov. 4 even as the U.S. presidential election results remain unsettled. Today's big move higher is largely due to huge gains for tech and healthcare ...
In case you are interested BIIB - S&P 500 Bucks Election Uncertainty, Rockets Higher on Tech Stock Surge; Huge Gains for Healthcare Stocks
* * $BIIB Video Chart 11-04-2020 * *
Link to Video - click here to watch the technical chart video
BIIB----BREAAAAAAAKOUT
Better Buy: Gilead Sciences vs. Biogen $BIIB $GILD
https://www.fool.com/investing/2020/04/03/better-buy-gilead-sciences-vs-biogen.aspx
Does the fda get a cut of this scam or what?
News: $BIIB Why Biogen Stock Surged Today
Shares of Biogen (NASDAQ: BIIB) rose sharply on Friday after the biotech company said its experimental Alzheimer's disease drug had been granted priority review status by the U.S. Food and Drug Administration (FDA). As of 3:25 p.m. EDT, Biogen's stock was up more than 10%. The pri...
Read the whole news BIIB - Why Biogen Stock Surged Today
News: $BIIB FDA Accepts Biogen's Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021 If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and TOKYO, Aug. 07, 202...
Got this from BIIB - FDA Accepts Biogen's Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
With Warren Buffet “in” makes you wonder if a few ears are being “tickled” at the FDA. If not this stock will fade right back down.
FDA proves corrupt beyond any and every measure with aduscambad approval. Injected possible
Brain swelling , zero provable benefit..
Yeah let’s make this happen!
Meanwhile Anavex’s safe and provable benefit drug gets starved a capital and attention.. one starts to believe the FDA and big pharma want us to die of dementia..
Sick conclusions to a sick fda decision
What a bunch of hyped up horseshet! I wouldnt take Biogens drug if it was the only therapy on earth!
Get ready, she’s setting up for a powerband straight up! All it needs is a PR so the funds can swap spit under cover, yet again,imho!
When are the HF’s going to blow BIIB smoke back up new unsuspecting investors arses? Maybe when they all get back from hoochin it up at the Hamptons?
Gotta get back to 300 to keep things “legit”!
AlphaPharm Biogenix products are a scam online. Dont try it because they will charge you recurring monthly fees.
AlphaPharm Biogenix products are a scam online. Dont try it because they will charge you recurring monthly fees.
AlphaPharm Biogenix products are a scam online. Dont try it because they will charge you recurring monthly fees.
this post was not meant for Biogen..sorry..too late to delete..
Followers
|
43
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
627
|
Created
|
11/17/07
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=BIIB
Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of neurology, oncology, immunology, cardiopulmonary, and hemophilia in the United States and internationally. The company?s marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, low-grade or follicular, CD20-positive, and B-cell Non-Hodgkin?s Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe psoriasis. Its products under development consist of BG-12, a Phase III clinical trial product for the treatment of MS; Humanized Anti-CD20 MAb, a Phase III clinical trial product for the treatment of rheumatoid arthritis and lupus nephritis; Lixivaptan, a Phase III clinical drug for the treatment of Hyponatremia; Daclizumab, a Phase II monoclonal antibody that is being tested in relapsing MS; and Fampridine, an oral compound as a treatment to improve walking ability in people with MS. The company?s products under preclinical stage comprise BIIB014, Ocrelizumab, Neublastin, LINGO, and BART for neurology; Hsp90 Inhibitor, GA101, Anti-IGF-1R, Volociximab, Anti-CRIPTO, RAF Inhibitor, and Anti-Fn14 for oncology; Anti-TWEAK, Anti-CD40L Fab, and Anti-FcRn for immunology; and Long-acting rFactor VIII for hemophilia. It has collaboration agreements with Neurimmune SubOne AG; Cardiokine Biopharma LLC; UCB, S.A.; Swedish Orphan Biovitrum AB; Facet Biotech Corporation; Vernalis plc; and Schering AG. The company was founded in 1985 and is based in Cambridge, Massachusetts.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |